The impact of peritoneal dialysis on oxypurinol and urate elimination in people with gout
Nephrology · 2024
DOI: 10.1111/nep.14306 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology, 2024. Verfasst von Luke C Wilson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Dunedin School of Medicine, Dunedin, New Zealand. Hauptthemen laut MEDLINE: Uric Acid, Gout, Peritoneal Dialysis, Oxypurinol. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Otago Medical Research Foundation Jack Thomson Award, Otago Medical Research Foundation.
Abstract (Originalsprache)
Gout affects 15%–30% of individuals with advanced kidney disease. Allopurinol which is rapidly and extensively metabolised to an active metabolite, oxypurinol, is the most commonly prescribed urate‐lowering therapy. Oxypurinol is almost entirely eliminated by the kidneys (>95%) and has an elimination half‐life of 18–30 h in those with normal kidney function. However, oxypurinol pharmacokinetics are poorly understood in individuals with kidney failure on peritoneal dialysis. This study characterised the elimination of oxypurinol and urate in people with gout receiving peritoneal dialysis. Oxypurinol steady‐state oral clearance (CL/F), elimination half‐life as well as kidney (CL k ) and peritoneal (CL pd ) clearances for oxypurinol and urate were calculated from the plasma, urine and dialysate concentration data for each individual. Our results demonstrate that oxypurinol and urate are removed by peritoneal dialysis, accounting for more than 50% of oxypurinol and urate clearances. An allopurinol dose about 50%–60% lower than the usual dose used for a patient with normal kidney function will provide adequate urate‐lowering therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Dunedin School of Medicine, Dunedin, New Zealand.
- School of Pharmacy, University of Otago, Dunedin, New Zealand.
- Sydney Pharmacy School, University of Sydney, Sydney, New South Wales, Australia.
- Department of Medicine, University of Otago, Christchurch, New Zealand.
- Department of Clinical Pharmacology & Toxicology, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
- Sydney Musculoskeletal Health, Univ. of Sydney, Sydney, New South Wales, Australia.
ORCID-Profile: Luke C Wilson, Daniel F B Wright, Suetonia C Green, Tracey L Putt, Robert J Walker
Förderung
- Otago Medical Research Foundation Jack Thomson Award
- Otago Medical Research Foundation
Zitieren
APA
Wilson, L. C., Ward, J., Wright, D. F. B., Green, S. C., Stocker, S. L., Putt, T. L., Schollum, J. B. W., & Walker, R. J. (2024). The impact of peritoneal dialysis on oxypurinol and urate elimination in people with gout. Nephrology. https://doi.org/10.1111/nep.14306
Vancouver
Wilson LC, Ward J, Wright DFB, Green SC, Stocker SL, Putt TL, et al. The impact of peritoneal dialysis on oxypurinol and urate elimination in people with gout. Nephrology. 2024. doi:10.1111/nep.14306
BibTeX
@article{Wilson2024,
author = {Wilson, Luke C and Ward, Jacob and Wright, Daniel F B and Green, Suetonia C and Stocker, Sophie L and Putt, Tracey L and Schollum, John B W and Walker, Robert J},
title = {The impact of peritoneal dialysis on oxypurinol and urate elimination in people with gout},
journal = {Nephrology},
year = {2024},
doi = {10.1111/nep.14306}
}
EUVIMED